{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:31:35Z","timestamp":1772177495935,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>The purpose of the present study was to estimate the prevalence of cyclin-dependent kinase (CDK) 4\/6 inhibitors use among cancer patients from the medication-related osteonecrosis of the jaw (MRONJ) cohort of the University of Messina. We retrospectively reviewed the records of all patients with either intravenous bisphosphonates or denosumab-related MRONJ reported in the electronic health records of the Unit of Oral Surgery, School of Dentistry, University of Messina between the first quarter of 2018 and the first quarter 2020 to identify eligible patients. We observed six cases of MRONJ associated with CDK4\/6 inhibitors concomitantly with intravenous bisphosphonates and\/or denosumab in breast cancer patients. The CDK4\/6 inhibitors registered were palbociclib (n = 5) and abemaciclib (n = 1). Data of cancer patients diagnosed with MRONJ in the same period (n = 10) were extracted for comparison. The comparative assessment with this group of patients showed a similar distribution of MRONJ stage ranged and clinical course after treatment. The degree of risk for osteonecrosis in patients taking these new classes of drugs is uncertain but warrants awareness and close monitoring. The role of premedication dental evaluation as a prevention strategy has been acknowledged for cancer patients about to initiate intravenous bisphosphonates and\/or denosumab for treatment of bone metastasis, but additional attention should be paid to whom are assuming CDK4\/6 inhibitors because of their oral adverse events.<\/jats:p>","DOI":"10.3390\/ijerph17249509","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T11:42:09Z","timestamp":1608291729000},"page":"9509","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Medication-Related Osteonecrosis of the Jaws and CDK4\/6 Inhibitors: A Recent Association"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5664-3118","authenticated-orcid":false,"given":"Antonia","family":"Marcian\u00f2","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"},{"name":"Humanitas Centro Catanese di Oncologia, Department of Medical Oncology, 95045 Misterbianco, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Marco","family":"Guzzo","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6995-6276","authenticated-orcid":false,"given":"Matteo","family":"Peditto","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Picone","sequence":"additional","affiliation":[{"name":"Humanitas Centro Catanese di Oncologia, Department of Medical Oncology, 95045 Misterbianco, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-1645","authenticated-orcid":false,"given":"Giacomo","family":"Oteri","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Venur, V.A., and Leone, J.P. (2016). Targeted Therapies for Brain Metastases from Breast Cancer. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17091543"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11912-019-0769-3","article-title":"CDK 4\/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions","volume":"21","author":"Spring","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer. Pivotal phase III trial leading to FDA approval of abemaciclib as first-line therapy for HR+ MBC","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in Hormone- Receptor-Positive Advanced Breast Cancer. Pivotal phase III trial leading to FDA approval of palbociclib in combination with fulvestrant for HR+ MBC","volume":"373","author":"Turner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.oooo.2018.11.012","article-title":"Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review","volume":"127","author":"King","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40265-015-0434-6","article-title":"Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK","volume":"75","author":"Califano","year":"2015","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1601-0825.2012.01903.x","article-title":"Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ)","volume":"18","author":"Bedogni","year":"2012","journal-title":"Oral Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Marcian\u00f2, A., Rubino, E., Peditto, M., Mauceri, R., and Oteri, G. (2020). Oral Surgical Management of Bone and Soft Tissues in MRONJ Treatment: A Decisional Tree. Life, 10.","DOI":"10.3390\/life10070099"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Rugani, P., Walter, C., Kirnbauer, B., Acham, S., Begus-Nahrman, Y., and Jakse, N. (2016). Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma. Dent. J., 4.","DOI":"10.3390\/dj4040032"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.amjmed.2008.01.047","article-title":"Factors associated with osteonecrosis of the jaw among bisphosphonate users","volume":"121","author":"Hess","year":"2008","journal-title":"Am. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.bdj.2015.680","article-title":"New cancer therapies and jaw necrosis","volume":"219","author":"Patel","year":"2015","journal-title":"Br. Dent. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.oooo.2017.10.010","article-title":"Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort","volume":"125","author":"Nielsen","year":"2018","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Oteri, G., Campisi, G., Panzarella, V., Morreale, I., Nucera, R., Di Fede, O., Picone, A., and Marcian\u00f2, A. (2018). Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients?. Biomed. Res. Int.","DOI":"10.1155\/2018\/4021952"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00520-017-3629-4","article-title":"Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors","volume":"25","author":"Vigarios","year":"2017","journal-title":"Support Care Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jbmr.2693","article-title":"Osteonecrosis of the Jaw in the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS)","volume":"31","author":"Zhang","year":"2016","journal-title":"J. Bone Min. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5125\/jkaoms.2017.43.2.120","article-title":"A rare case of osteonecrosis of the jaw related to imatinib","volume":"43","author":"Viviano","year":"2017","journal-title":"J. Korean Assoc. Oral Maxillofac. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tripleo.2011.06.023","article-title":"Sunitinib related osteonecrosis of jaw: A case report","volume":"113","author":"Fleissig","year":"2012","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"Oral Maxillofac. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","article-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: Presentation of 3 cases","volume":"110","author":"Hoefert","year":"2010","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.5301\/tj.5000504","article-title":"Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma","volume":"102","author":"Garuti","year":"2016","journal-title":"Tumori J."},{"key":"ref_24","first-page":"29","article-title":"Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib\u2014A case report with clinical implications","volume":"4","author":"Razis","year":"2013","journal-title":"Forum Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Antonuzzo, L., Lunghi, A., Giommoni, E., Brugia, M., and Di Costanzo, F. (2016). Regorafenib Also Can Cause Osteonecrosis of the Jaw. J. Natl. Cancer Inst., djw002.","DOI":"10.1093\/jnci\/djw002"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/adj.12254","article-title":"Osteonecrosis of the jaw in a patient receiving cabozantinib","volume":"60","author":"Marino","year":"2015","journal-title":"Aust. Dent. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.ijom.2019.07.010","article-title":"Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib","volume":"48","author":"Mauceri","year":"2019","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/14737140.2017.1355242","article-title":"Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: A systematic review and meta-analysis","volume":"17","author":"Lasheen","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination with Fulvestrant in Women with HR+\/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Basile, D., Di Nardo, P., Corvaja, C., Garattini, S.K., Pelizzari, G., Lisanti, C., Bortot, L., Da Ros, L., Bartoletti, M., and Borghi, M. (2019). Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers, 11.","DOI":"10.3390\/cancers11060857"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.oooo.2018.02.003","article-title":"Medication-related osteonecrosis of the jaw: An update on the memorial Sloan Kettering cancer center experience and the role of premedication dental evaluation in prevention","volume":"125","author":"Owosho","year":"2018","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/24\/9509\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:46:58Z","timestamp":1760179618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/24\/9509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":31,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["ijerph17249509"],"URL":"https:\/\/doi.org\/10.3390\/ijerph17249509","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]}}}